RNA-seq data were deposited in the Gene Expression Omnibus database under accession ID GSE132121.

Introduction {#sec001}
============

Genome integrity in the germline is important for intact transmission of genetic information into progeny. However, it is being disturbed by retrotransposons, mobile genomic parasites reproducing through a "copy & paste" strategy (reviewed in \[[@pgen.1008261.ref001]\]). Although retrotransposons threaten genome integrity, they occasionally also provide new functional gene elements, such as promoters, enhancers, exons, splice junctions, or polyA signals, thus contributing to evolution of new traits (reviewed in \[[@pgen.1008261.ref001]\]). Retrotransposons can be categorized by the presence of long terminal repeats (LTRs) and retrotransposition autonomy \[[@pgen.1008261.ref002]\]. While contributions of different families vary, their collective contribution to the mammalian genome content is substantial: annotatable retrotransposon insertions comprise about a half of human and mouse genomes \[[@pgen.1008261.ref003], [@pgen.1008261.ref004]\]. The mouse genome hosts two mobile autonomous retrotransposons: non-LTR element LINE-1 (L1) and LTR element Intracisternal A Particle (IAP) \[[@pgen.1008261.ref005]--[@pgen.1008261.ref007]\]. L1 (reviewed in \[[@pgen.1008261.ref008]\]) is the most successful mammalian autonomous retrotransposon with 868,000 insertions in the mouse genome \[[@pgen.1008261.ref004]\]. L1 has several unique adaptations, such as a unique complex bidirectional promoter \[[@pgen.1008261.ref009], [@pgen.1008261.ref010]\] and retrotransposition in *cis* \[[@pgen.1008261.ref011]\]. IAP is an endogenous retrovirus, which invaded the mouse genome relatively recently \[[@pgen.1008261.ref006]\]. RepeatMasker identifies approximately 13,000 IAP insertions, of which 44% represent solo LTRs \[[@pgen.1008261.ref012]\].

Various transcriptional and post-transcriptional mechanisms evolved to repress retrotransposons (reviewed in \[[@pgen.1008261.ref013]\]). A key mechanism suppressing retrotransposons in the mammalian germline is the PIWI-interacting RNA (piRNA) pathway, which combines post-transcriptional and transcriptional silencing (reviewed in \[[@pgen.1008261.ref014]\]). The piRNA pathway relies on specific genomic regions (piRNA clusters) that are sensing invading mobile elements and giving rise to piRNAs. These are 25--30 nucleotides long RNAs loaded onto PIWI subgroup of the Argonaute protein family, which guide retrotransposon recognition and repression \[[@pgen.1008261.ref015]\]. A complex piRNA system starts with processing primary transcripts from piRNA clusters into piRNAs, which guide cleavage of retrotransposon transcripts. This triggers production of a secondary piRNA pool, which further facilitate processing of primary transcripts into piRNAs (reviewed in \[[@pgen.1008261.ref014]\]).

Mice use three PIWI proteins PIWIL1 (MIWI), PIWIL2 (MILI), and PIWIL4 (MIWI2). PIWIL3, the fourth mammalian PIWI protein, was found in bovine oocytes \[[@pgen.1008261.ref016]\] but *Piwil3* gene was apparently lost in the common ancestor of mice and rats. All three mouse PIWI proteins are essential for spermatogenesis but not oogenesis \[[@pgen.1008261.ref017]--[@pgen.1008261.ref019]\] although the piRNA pathway operates during oogenesis where it targets retrotransposon expression \[[@pgen.1008261.ref020], [@pgen.1008261.ref021]\]. MILI is a cytoplasmic protein, which generates primary piRNAs and secondary piRNAs by so-called ping-pong mechanism with itself or with MIWI2 \[[@pgen.1008261.ref022]--[@pgen.1008261.ref024]\]. MIWI2 shuttles to the nucleus and mediates transcriptional silencing through DNA and histone methylation of retrotransposon loci \[[@pgen.1008261.ref025], [@pgen.1008261.ref026]\]. In males, MIWI2 expression ceases around birth whereas MILI is important for clearance of retrotransposon transcripts in postnatal testes \[[@pgen.1008261.ref024], [@pgen.1008261.ref027]\]. MILI and MIWI2 cooperate on silencing of L1 and IAP (non-LTR and LTR) retrotransposons in mouse fetal testes \[[@pgen.1008261.ref028], [@pgen.1008261.ref029]\].

It is unknown what accounts for the strikingly different phenotypes of piRNA pathway mutants in murine male and female germlines. In contrast to mice, *Drosophila* or zebrafish females lacking piRNA pathway components are sterile \[[@pgen.1008261.ref017]--[@pgen.1008261.ref019], [@pgen.1008261.ref030]\]. It was hypothesized that the loss of the piRNA pathway in the mouse female germline could be compensated by RNA interference (RNAi) \[[@pgen.1008261.ref031], [@pgen.1008261.ref032]\]. Canonical RNAi is defined as sequence-specific RNA degradation induced by long double-stranded RNA (dsRNA) \[[@pgen.1008261.ref033]\] and is active in mouse oocytes \[[@pgen.1008261.ref034], [@pgen.1008261.ref035]\]. The canonical RNAi starts with processing of long dsRNA by RNase III Dicer into \~22 nucleotides long small interfering RNAs (siRNAs), which guide sequence-specific cleavage of perfectly complementary RNAs by Argonaute 2 (AGO2) (reviewed in \[[@pgen.1008261.ref036]\]). Endogenous RNAi in mouse oocytes and zygotes was shown to target mobile elements and regulate gene expression \[[@pgen.1008261.ref031], [@pgen.1008261.ref032], [@pgen.1008261.ref037]--[@pgen.1008261.ref040]\]. For example, L1 can be targeted in oocytes by piRNAs and endo-siRNAs \[[@pgen.1008261.ref032], [@pgen.1008261.ref040]--[@pgen.1008261.ref043]\]. Analysis of small RNA sequencing (RNA-seq) data from mouse oocytes \[[@pgen.1008261.ref043]\] shows that piRNA and RNAi pathways may target retrotransposons simultaneously but the extent of repression for individual retrotransposons by each pathway could vary ([Fig 1](#pgen.1008261.g001){ref-type="fig"}). Importantly, endogenous RNAi in mouse oocytes evolved during rodent evolution through exaptation of an MT retrotransposon insertion in intron 6 of *Dicer* gene, which functions as an oocyte-specific promoter producing a unique truncated Dicer isoform (denoted Dicer^O^). *Dicer*^O^ transcripts accumulate during oocyte's growth and persist into the zygote \[[@pgen.1008261.ref044]\]. Based on RNA-seq, *Dicer*^O^ is expressed already in non-growing oocytes 5 days postpartum (5dpp) \[[@pgen.1008261.ref045]\].

![Retrotransposon-derived small RNAs.\
Different retrotransposons are associated with different length distribution of small RNAs from mouse oocytes suggesting partially redundant repression of retrotransposons by endogenous RNAi and piRNA pathways. Based on RNA-seq data from Yang et al., 2016 \[[@pgen.1008261.ref043]\].](pgen.1008261.g001){#pgen.1008261.g001}

To address the significance of RNAi and piRNA pathway redundancy, we produced and analyzed mice lacking both pathways. We first produced a novel mouse model lacking *Dicer*^O^ (denoted *Dicer*^SOM^) and then crossed it with *Mili*^DAH^ mice expressing catalytically inactive MILI \[[@pgen.1008261.ref024]\]. We show that engagement of piRNA and RNAi pathway in repression of retrotransposons is stochastic and occasionally synergic. The simultaneous loss of RNAi and piRNA pathways uncovers redundant targeting of L1 and extended L1 derepression but does not affect oocyte development. Thus, while piRNAs are essential for spermatogenesis and show restricted redundancy with RNAi, they do not have essential role in ovarian oocyte development that would be masked by RNAi.

Results {#sec002}
=======

Generation of Dicer^SOM^ mice---A novel RNAi-deficient model {#sec003}
------------------------------------------------------------

The oocyte-specific Dicer^O^ isoform comprises the majority of Dicer protein in mouse oocytes and deletion of its LTR-derived promoter (*Dicer*^ΔMT^ mutant) phenocopies conditional *Dicer* knock-out in mouse oocytes \[[@pgen.1008261.ref038], [@pgen.1008261.ref044]\]. However, we have discovered that there is a second LTR insertion (MTA) in intron 6 ([Fig 2A](#pgen.1008261.g002){ref-type="fig"}), which can also produce a truncated Dicer variant and reduce phenotype penetrance in *Dicer*^ΔMT/ΔMT^ mice \[[@pgen.1008261.ref046]\]. Thus, to eliminate truncated Dicer expression in mouse oocytes, we generated another modified *Dicer* allele (denoted *Dicer*^SOM^), which has an HA-tag at the N-terminus and lacks introns 2--6 ([Fig 2A](#pgen.1008261.g002){ref-type="fig"}). It was shown that N-terminal HA-tag on Dicer does not produce a phenotype and allows for its detection with highly-specific anti-HA antibodies \[[@pgen.1008261.ref047]\].

![*Dicer*^SOM^ mouse model.\
(A) Schematic depiction of the 5' gene structure of *Dicer* and *Dicer*^yΔMT^ and *Dicer*^SOM^ models. *Dicer*^SOM^ model was produced by removing \~6.5 kb of genomic DNA using CRISPR nucleases followed by homologous recombination with a construct encoding an HA-tag and exons 2--7. The resulting allele lacks introns 2 to 6 while encoding HA-tagged full-length Dicer. (B) *Dicer*^SOM^ mice express HA-tagged full-length Dicer. 40 μg of total protein lysate were loaded per lane and loading consistency was confirmed by Ponceau S staining of the Western blot membrane (lower panel). (C) Dicer^SOM^ protein has cytoplasmic expression. Shown are sections of seminiferous tubules stained with anti-HA antibody revealing cytoplasmic Dicer^SOM^ signal (red color) in spermatogonia of *Dicer*^SOM/SOM^ mice. DNA was stained with DAPI (blue color). (D) *Dicer*^SOM/SOM^ animals are born in a Mendelian ratio upon crossing *Dicer*^SOM/wt^ parents. (E) Analysis of Dicer expression by qPCR in oocytes of homozygous *Dicer*^ΔMT^ and *Dicer*^SOM^ mutants. Bar colors indicate cDNA region amplified by primers localized in exons as described in the x-axis legend. *Dicer*^ΔMT/ΔMT^ mice show loss of expression of the MTC-driven Dicer variant and a relative increase of expression from the downstream MTA LTR insertion. *Dicer*^SOM/SOM^ mice show complete loss of short Dicer isoform. Data from three biological replicates were normalized to oocytes from heterozygous littermates. Error bar = SD. (F) Analysis of Dicer expression in oocytes of wild-type animals and homozygous *Dicer*^ΔMT^ and *Dicer*^SOM^ mutants by RNA-seq (three biological replicates). Depicted are RPKM values per exon. Error bar = SD.](pgen.1008261.g002){#pgen.1008261.g002}

*Dicer*^SOM^ allele was generated in mouse embryonic stem cells (ESCs) by cleaving intron 2 and intron 6 with Cas9 nuclease followed by homologous recombination with a construct carrying an HA-tag fused to the 5' end of *Dicer* cDNA containing coding sequence of exon 2 to exon 7. Homologous recombination arms contained intron 1 and intron 7 ([Fig 2A](#pgen.1008261.g002){ref-type="fig"}). An ESC line carrying the desired recombination event ([S1 Fig](#pgen.1008261.s002){ref-type="supplementary-material"}) was subsequently used to make mouse chimaeras from which we established a mouse line. Analysis of *Dicer*^SOM^ mice showed that the full-length HA-tagged Dicer could be detected by Western blotting in organ lysates ([Fig 2B](#pgen.1008261.g002){ref-type="fig"}) and by immunofluorescent staining of histological sections albeit the signal was relatively low with the protocol and antibody used ([Fig 2C](#pgen.1008261.g002){ref-type="fig"}). Breeding of *Dicer*^SOM/wt^ animals yielded progeny with *Dicer*^SOM/SOM^ genotypes at the expected Mendelian ratio ([Fig 2D](#pgen.1008261.g002){ref-type="fig"}). *Dicer*^SOM/SOM^ mice appeared normal and males were fertile suggesting that the introduced modification did not perturb normal full-length Dicer function. Importantly, *Dicer*^SOM/SOM^ females were sterile, which was the expected phenotype caused by the lack of Dicer^O^. Analysis of *Dicer*^SOM/SOM^ oocytes by qPCR and RNA-seq showed the loss of *Dicer*^O^-encoding transcript and minimal levels of the full-length Dicer isoform mRNA, which contrasted with *Dicer*^ΔMT/ΔMT^ oocytes where expression from the MTA LTR was enhanced ([Fig 2E and 2F](#pgen.1008261.g002){ref-type="fig"}). Thus, *Dicer*^SOM/SOM^ mice solved the problem with residual Dicer^O^ expression observed in *Dicer*^ΔMT/ΔMT^ mice.

*Dicer*^SOM^ mutants phenocopy oocyte-specific *Dicer* knock-out {#sec004}
----------------------------------------------------------------

Next, we analyzed the phenotype of *Dicer*^SOM/SOM^ oocytes and compared that with known phenotypes of *Dicer* and *Ago2* mutants, which all exhibit sterility and spindle defects while having different impact on oocyte's small RNA biogenesis and suppression of their targets \[[@pgen.1008261.ref031], [@pgen.1008261.ref038], [@pgen.1008261.ref044]\]. Fully-grown *Dicer*^SOM/SOM^ oocytes showed high frequency of meiotic spindle defects upon resumption of meiosis ([Fig 3A and 3B](#pgen.1008261.g003){ref-type="fig"} and [S2 Fig](#pgen.1008261.s003){ref-type="supplementary-material"}) and upregulated mRNA levels of RNAi targets ([Fig 3C](#pgen.1008261.g003){ref-type="fig"}), consistent with RNAi pathway deficiency. For precise characterization of transcriptome changes in *Dicer*^SOM/SOM^ oocytes, we performed RNA-seq of fully-grown germinal vesicle-intact (GV) oocytes. When comparing mRNA changes in *Dicer*^ΔMT/ΔMT^ and *Dicer*^SOM/SOM^ oocytes, the later showed more deregulated transcriptome ([Fig 3D](#pgen.1008261.g003){ref-type="fig"}). In addition, we observed upregulated mRNAs of many genes, which would have potential to be targeted by RNAi ([Fig 3D](#pgen.1008261.g003){ref-type="fig"}, red points), i.e. genes where complementary endo-siRNAs were identified in RNA-seq datasets from mouse oocytes \[[@pgen.1008261.ref032], [@pgen.1008261.ref041], [@pgen.1008261.ref043]\]. This was consistent with the principal component analysis (PCA) where *Dicer*^ΔMT/ΔMT^ samples localized between wild-type and *Dicer*^SOM/SOM^ samples ([Fig 3E](#pgen.1008261.g003){ref-type="fig"}). We included into PCA also transcriptomes of previously analyzed *Dicer* and *Ago2* mutants \[[@pgen.1008261.ref031]\]. Although the experimental variability ("bench effect") separated our and other datasets along the PC1 axis, the data showed an apparent separation of wild-type and RNAi mutant samples along the PC2 axis. *Dicer*^SOM/SOM^ transcriptome appeared to be more distant from wild-type samples than *Dicer*^ΔMT/ΔMT^ transcriptome and in a parallel position with Stein et al. mutants \[[@pgen.1008261.ref031]\] relative to wild-type samples ([Fig 3E](#pgen.1008261.g003){ref-type="fig"}).

![*Dicer*^SOM/SOM^ animals phenocopy oocyte-specific Dicer knock-out.\
(A) Oocytes of *Dicer*^SOM/SOM^ mice exhibit spindle defects like *Dicer*^−/−^ or *Dicer*^ΔMT/ΔMT^ oocytes \[[@pgen.1008261.ref038], [@pgen.1008261.ref039], [@pgen.1008261.ref044]\]. Size bar = 10 μm. (B) Frequency of meiotic spindle defects in oocytes from *Dicer*^SOM/wt^ and *Dicer*^SOM/SOM^ mice. Numbers correspond to examined oocytes with each genotype. (C) mRNA expression of selected RNAi targets analyzed by qPCR performed as three biological replicates. *B2m* is a non-targeted gene. All mRNA levels are shown relative to *Hprt1*. (D) MA plots depicting transcriptome changes in *Dicer*^ΔMT/ΔMT^ and *Dicer*^SOM/SOM^ oocytes relative to wild-type oocytes. (E) PCA analysis of RPKM transcriptome changes in oocytes of different mutants, which includes previously published data from *Dicer* and *Ago* mutants \[[@pgen.1008261.ref031]\]. (F) Comparison of mRNA expression changes in *Dicer*^ΔMT/ΔMT^ and *Dicer*^*S*OM/SOM^ oocytes (x-axis) with mRNA changes in oocytes with conditional Dicer knock-out (y-axis). (G) Correlation matrices of retrotransposon-derived transcriptome in different mutant oocytes. Elliptic shapes reflect sizes of inscribed correlation coefficients for easier visual navigation.](pgen.1008261.g003){#pgen.1008261.g003}

When comparing relative transcriptome changes of Dicer mutants to accompanying wild-type controls ([Fig 3F](#pgen.1008261.g003){ref-type="fig"} and [S3 Fig](#pgen.1008261.s004){ref-type="supplementary-material"}), *Dicer*^ΔMT/ΔMT^ and *Dicer*^SOM/SOM^ showed good overall correlation with transcriptome changes in *Dicer*^−/−^ oocytes (r = 0.75) and relative changes of predicted RNAi targets correlated slightly better in *Dicer*^SOM/SOM^ (r = 0.89) than changes in *Dicer*^ΔMT/ΔMT^ (r = 0.86) oocytes. While the difference in correlation coefficient is minimal, putative RNAi targets and other upregulated genes tend to be distributed above the diagonal when comparing *Dicer*^*ΔMT/ΔMT*^ and *Dicer*^*−/−*^ samples and more along it when comparing *Dicer*^SOM/SOM^ with *Dicer*^−/−^ ([Fig 3F](#pgen.1008261.g003){ref-type="fig"}). This means that transcriptome changes in *Dicer*^SOM/SOM^ better mimic changes in *Dicer*^*−/−*^ than transcriptome changes in *Dicer*^ΔMT/ΔMT^ and show that *Dicer*^SOM/SOM^ model is superior to *Dicer*^ΔMT/ΔMT^ as oocyte-specific RNAi deficiency model. As RNAi also targets repetitive sequences, we analyzed correlations of relative changes of retrotransposon RNAs in our datasets and *Dicer* and *Ago2* mutants \[[@pgen.1008261.ref031]\]. In this case, *Dicer*^SOM/SOM^ mutants correlated with *Dicer*^*−/−*^ mutant (r = 0.90) even better than *Dicer*^*−/−*^ mutant with *Ago2* mutants ([Fig 3G](#pgen.1008261.g003){ref-type="fig"}), which is remarkable considering entirely independent experimental analysis. Since *Dicer*^SOM/SOM^ females closely phenocopy conditional *Dicer* knock-out in oocytes, the *Dicer*^SOM^ model is excellent for studying simultaneous loss of RNAi and piRNA pathways in oocytes because it overcomes arduous breeding of the *Mili*^DAH^ model with a conditional *Dicer* knock-out.

RNAi & piRNA mutant females show no signs of disturbed ovarian development of oocytes {#sec005}
-------------------------------------------------------------------------------------

Mouse mutants lacking piRNA and RNAi pathways in mouse oocytes should reveal whether or not mutants of single pathways manifest the full extent of small RNA-mediated retrotransposon repression because both pathways can suppress mobile elements. Accordingly, we crossed *Dicer*^SOM^ mice with *Mili*^DAH^ mice carrying a mutation in the DDH catalytic triad of MILI where the second aspartic acid is mutated to an alanine \[[@pgen.1008261.ref024]\]. As *Mili*^DAH/DAH^ males and *Dicer*^SOM/SOM^ females are sterile, we first crossed *Mili*^DAH/DAH^ females to *Dicer*^SOM/SOM^ males (both on C57Bl/6 background) and then crossed their double heterozygote progeny to obtain *Dicer*^SOM/WT^, *Mili*^DAH/DAH^ females and Dicer^SOM/SOM^, *Mili*^DAH/WT^ males, which were crossed to obtain females lacking in oocytes both pathways (*Dicer*^*SOM/SOM*^, *Mili*^DAH/DAH^, "double KO"), only RNAi (*Dicer*^SOM/SOM^, *Mili*^DAH/WT^), only piRNA (*Dicer*^SOM/WT^, *Mili*^DAH/DAH^), or none (*Dicer*^SOM/WT^, *Mili*^DAH/WT^). Importantly, phenotype analysis of double mutants was restricted to ovarian phenotypes manifested until the fully-grown GV oocyte stage because the loss of RNAi causes meiotic spindle defects in ovulated oocytes and impairs further development \[[@pgen.1008261.ref038], [@pgen.1008261.ref039], [@pgen.1008261.ref044]\].

Females of the four above-described genotypes were analyzed for ovarian weight and histology and number of fully-grown GV oocytes recovered from non-superovulated animals ([Fig 4A--4C](#pgen.1008261.g004){ref-type="fig"}). Double KO females showed normal ovarian morphology and weight of ovaries ([Fig 4A and 4B](#pgen.1008261.g004){ref-type="fig"}). The presence of antral follicles and *corpora lutea* in ovaries of double KO females suggested that the loss of RNAi on the piRNA knock-out background does not reveal a strong ovarian phenotype. This was further supported by recovering normal number of fully-grown oocytes from double KO ovaries ([Fig 4C](#pgen.1008261.g004){ref-type="fig"}). Elimination of both pathways thus did not significantly affect follicular growth and ovarian oocyte development ([Fig 4D](#pgen.1008261.g004){ref-type="fig"}), which shows that RNAi pathway does not mask an essential function of piRNAs during ovarian oogenesis.

![RNAi (*Dicer*^SOM/SOM^) and piRNA (*Mili*^DAH/DAH^) knock-out analysis.\
(A) Representative histological sections of ovaries stained with hematoxylin and eosin. Abbreviations: CL--*corpus luteum*, EA---early antral follicle, AF---antral follicle. (B) Ovarian weight. Ten ovaries from five 14--19 weeks-old females were analyzed per genotype. (C) Yield of fully-grown germinal vesicle (GV)-intact oocytes per animal. Seven 10--16 weeks old females per genotype were analyzed. (D) Analysis of follicles in ovaries of mutant animals. Follicular content has been normalized per average ovarian section area per animal. Six ovaries from three animals were analyzed. Error bar = SD.](pgen.1008261.g004){#pgen.1008261.g004}

Varying redundancy of retrotransposon repression by RNAi and piRNA pathways {#sec006}
---------------------------------------------------------------------------

To complete the analysis of double mutants, we examined retrotransposon transcript levels. Previous studies showed upregulation of specific retrotransposon types in single pathway mutants but the extent to which retrotransposons are simultaneously regulated and how one pathway could compensate for the loss of the other one was not clear. We analyzed by qPCR active subfamilies of autonomous retrotransposon L1 (L1Md_T) and IAP (IAPEz) and selected non-autonomous elements SINE B1, RLTR10, and MTA. Comparison of oocytes of the four genotypes (double KO, RNAi KO, piRNA KO, and double heterozygote) showed interesting diversity of transcript level changes ([Fig 5A](#pgen.1008261.g005){ref-type="fig"}).

![Transcriptional changes in oocytes lacking RNAi and piRNA pathways.\
(A) qPCR analysis of selected retrotransposons in mutant oocytes. Retrotransposon RNA levels are shown relative to that in heterozygous (*Mili*^DAH/WT^, *Dicer*^SOM/WT^) oocytes. Three biological replicates were perfomed. Error bar = SD. (B) PCA analysis of RPKM transcriptome changes in oocytes with mutated RNAi (*Mili*^DAH/WT^, *Dicer*^SOM/SOM^), piRNA (*Mili*^DAH/DAH^, *Dicer*^SOM/WT^) or both pathways (*Mili*^DAH/DAH^, *Dicer*^SOM/SOM^). Oocytes from heterozygous littermates (*Mili*^DAH/WT^, *Dicer*^SOM/WT^) served as controls. (C) MA plot depicting transcriptome changes in double mutant oocytes relative to RNAi pathway mutant oocytes. MA plots depicting transcriptome changes of pathway mutants relative to heterozygous control are provided in [S3 Fig](#pgen.1008261.s004){ref-type="supplementary-material"}. Transcripts with significantly higher and lower transcript levels are shown in red and blue, respectively and are provided in the Supplementary file 1. Transcripts from a tandem duplication cluster at chromosome 12 are depicted as triangles. One such a transcript was chosen for display in the panel E. Transcript labeled with D is associated with a *Mili*-dependent small RNA cluster. (D) A UCSC browser snapshot of a region producing *Mili*-dependent and *Mili*-independent small RNAs. The locus encodes non-coding RNAs (*Gm476432* and *Gm17821*), which show increased abundance in double mutants. The upper part shows RNA-seq data from oocytes with the four genotypes. Dashed horizontal lines depict expression level corresponding to 100 counts per million (CPM). The lower two samples show small RNAs from wild-type and *Mili*-mutant postnatal ovaries (day 20) from Kabayama et al. \[[@pgen.1008261.ref021]\]. The *Mili*^DAH/DAH^ mutant is the same one as in our study. The bottom part depicts distribution of repetitive elements along the locus with a blue arrow pointing to the LTRIS_Mm inverted repeat giving rise to *Mili*-independent 21--23 nt small RNAs. (E) An example of one of the paralogs from the tandem duplication cluster at chromosome 12, which exhibit increased transcript levels in double mutants. The upper part shows the tandem duplication cluster at chromosome 12, the lower half shows a snapshot from a UCSC browser with scaled RNA-seq data from different mutants. Expression analysis data from UCSC browser are organized as in the panel D. The bottom part depicts distribution of SINE, LINE and LTR retrotransposons and MurSatRep1 repeat along the locus. (F) RNA abundance of selected retrotransposon types from Repeatmasker annotation in mutant oocytes are displayed relative to heterozygous (*Mili*^DAH/WT^, *Dicer*^SOM/WT^) controls.](pgen.1008261.g005){#pgen.1008261.g005}

IAP seemed to be targeted by the piRNA pathway and was even better suppressed in RNAi knock-out oocytes. Levels of IAPs internal sequence showed low if any increase when RNAi was lost in addition to the piRNA pathway ([Fig 5A](#pgen.1008261.g005){ref-type="fig"}). A strong effect of double knock-out was observed on L1Md_T expression. While RNAi knock-out had no effect and *Mili* knock-out showed only slightly increased L1 expression, the loss of both pathways caused about six-fold increase in expression suggesting that both pathways target L1 and can mutually compensate loss of a single pathway. In contrast, RNAi primarily targeted RLTR10. *Mili* knock-out had no effect on RLTR10 expression on its own but had minor additive effect on *Dicer*^SOM/SOM^ background ([Fig 5A](#pgen.1008261.g005){ref-type="fig"}). These data suggest that RNAi and piRNA pathways suppress some but not all retrotransposons in a redundant manner and can partially compensate for each other's loss.

To obtain an independent confirmation of qPCR data, we performed RNA-seq analysis of the four genotypes. The first component of a PCA analysis showed that transcriptomes of double mutants were quite similar to RNAi mutants while the loss of that piRNA pathway had a minor effect ([Fig 5B](#pgen.1008261.g005){ref-type="fig"}). These results were consistent with a more detailed survey of transcriptome changes in individual mutants ([S4 Fig](#pgen.1008261.s005){ref-type="supplementary-material"}). Given the PCA results and our interest in understanding of the phenotype of the double mutant, we focused on transcriptome changes in double mutant oocytes relative to RNAi mutants. This analysis revealed that a small population of genes (127 genes) exhibited significantly increased transcript abundance on top of gene expression changes caused by the loss of RNAi ([Fig 5C](#pgen.1008261.g005){ref-type="fig"} and [S1 Table](#pgen.1008261.s009){ref-type="supplementary-material"}).

The most interesting locus exemplifying a gene coupling RNAi and piRNA pathways included lncRNAs *Gm47732* add *Gm17821* ([Fig 5D](#pgen.1008261.g005){ref-type="fig"}). Both lncRNAs showed increased transcript abundance in double mutants. *Gm17821* apparently overlaps with a primary unidirectional piRNA cluster as evidenced by *Mili*-dependent maternal piRNAs \[[@pgen.1008261.ref021]\]. At the same time, *Gm17821* intron contains an inverted repeat of two LTRIS_Mm sequences, which gives rise to *Mili*-independent 21--23 nt small RNAs ([Fig 5D](#pgen.1008261.g005){ref-type="fig"}). Therefore, this locus produces primary piRNA transcripts, which are also processed by RNAi machinery.

Other genes, which had increased expression in double mutants were a mixture of protein coding genes and long non-coding RNAs. Although many transcripts carried L1 or IAP sequences in 3'UTRs, it is unclear whether they represent genes simultaneously regulated by RNAi and piRNA pathways. One interesting observation worth of further investigation was increased abundance of over twenty long non-coding RNA (lncRNA) distinct paralogs, which carried MurSatRep1 repetitive sequence in their last exon and localized into a large (6.7 MB) and complex segmental duplication locus on mouse chromosome 12 ([Fig 5E](#pgen.1008261.g005){ref-type="fig"}).

Analysis of repetitive sequences in RNA-seq data also corroborated previous qPCR analysis ([Fig 5F](#pgen.1008261.g005){ref-type="fig"}). This included dominating piRNA-dependent suppression of IAP elements where the loss of RNAi even improved suppression of different IAP subgroups while the loss of both pathways had caused higher IAP expression than the loss of the piRNA pathway alone. RLTR10 and MaLR elements were primarily targeted by RNAi while L1 elements showed the strongest redundancy of RNAi and piRNA pathways; only a combined suppression of both pathways yielded increased abundance of L1 sequence ([Fig 5F](#pgen.1008261.g005){ref-type="fig"}). RNA-seq data thus confirmed that RNAi and piRNA pathways suppress some but not all retrotransposons in a redundant manner and compensate for each other's loss particularly in the case of L1 elements. At the same time, even when both pathways simultaneously fail to suppress retrotransposons in non-growing oocytes or during oocyte growth, this does not lead to a failure of ovarian oogenesis.

Minimal expression of autonomous retrotransposition-competent L1s in mouse oocytes {#sec007}
----------------------------------------------------------------------------------

The lack of sterile phenotype in female mice upon removal of two pathways targeting retrotransposons could stem from specific behavior/repression of DNA-damaging retrotransposons in the mouse female germline, which would make it less sensitive to the loss of the piRNA pathway. Expression of retrotransposons can differ between male and female germlines as retrotransposons adapt their transcriptional control to transcription factors regulating gene expression during different parts of the germline cycle. It can be observed in RNA-seq data \[[@pgen.1008261.ref045], [@pgen.1008261.ref048]--[@pgen.1008261.ref050]\]. Mouse oocytes have relatively low expression of L1 and IAP ([Fig 6A](#pgen.1008261.g006){ref-type="fig"}). Mouse genome contains several L1 families, of which LINE1_Md_A, LINE1_Md_T(-F) and LINE1_Md_G(-F) are the most recent and contain full-length retrotransposition-competent LINE1 copies \[[@pgen.1008261.ref051]--[@pgen.1008261.ref053]\]. Remarkably, despite the number of genomic insertions, the contribution of L1 sequences from these subfamilies to the oocyte transcriptome is relatively low, generally not exceeding 50 reads per million ([Fig 6B](#pgen.1008261.g006){ref-type="fig"}). While the double mutants show about an order of magnitude higher L1 RNA abundance ([Fig 6B](#pgen.1008261.g006){ref-type="fig"}), these sequences could originate from transcribed insertions that cannot retrotranspose.

![Retrotransposon expression in the female germline.\
(A) Relative retrotransposon expression during the germline cycle. The heatmap was produced as described previously \[[@pgen.1008261.ref046]\] using published expression data \[[@pgen.1008261.ref045], [@pgen.1008261.ref048]--[@pgen.1008261.ref050]\]. Depicted L1 and IAP retrotransposon subfamilies have full-length intact retrotransposon insertions in C57Bl/6 genome. (B) Selected L1 retrotransposon contribution to transcriptomes of double mutants (*Mili*^DAH/DAH^, *Dicer*^SOM/SOM^) and controls (*Mili*^DAH/WT^, *Dicer*^SOM/WT^). Four biological replicates. Error bar = SD. (C) Most expressed intact L1 retrotransposons from the four most abundant subfamilies. Shown are UCSC genome browser snapshots of specific L1 insertions with the highest coverage by RNA-seq reads in double mutants. The samples (from the top) depict merged data from 125 nucleotide paired-end (125PE) sequencing of normal full-grown GV oocytes from Horvat et al. \[[@pgen.1008261.ref054]\], 75 nucleotide paired-end (75PE) sequencing of controls (*Mili*^DAH/WT^, *Dicer*^SOM/WT^) and double mutants (*Mili*^DAH/DAH^, *Dicer*^SOM/SOM^) from this study, and 50 nucleotide single-end (50SE) sequencing of total transcriptome of 10 days old wild-type and *Mili*^---/---^ testes \[[@pgen.1008261.ref028]\]. All RNA-seq data were scaled and are shown at the same scale 5 CPM indicated by the dashed line. L1 schemes are depicted with ORF1 and ORF2 as lighter and darker grey rectangle, respectively.](pgen.1008261.g006){#pgen.1008261.g006}

We thus examined expression of all full-length L1 elements with intact ORF in the reference C57Bl/6 genome in fully-grown oocytes by mapping our RNA-seq libraries directly on these elements (using RNA-seq of mutants from this work and from \[[@pgen.1008261.ref054]\]). While RNA-seq analysis cannot directly distinguish between reads originating from "dead" elements and intact ones, coverage by perfectly mapping reads still allows to assess how strong is the evidence supporting expression of intact, retrotransposition-competent elements. We thus focused on those intact elements exhibiting not only high expression in the number of reads per element but also the highest coverage of the entire element by RNA-seq data from double mutants (depth \~ 175x10^6^ perfectly matched 75 nt paired-end (75PE) sequenced fragments). We also included previous RNA-seq data from control and *Mili*-deficient postnatal day 10 (P10) testes \[[@pgen.1008261.ref028]\].

The L1 elements showing the highest coverage by RNA-seq data in double mutants exhibited minimal coverage in normal fully grown oocytes ([Fig 6C](#pgen.1008261.g006){ref-type="fig"}). In fact, analysis using perfectly-mapping reads from 125 nucleotide paired-end sequencing of fully-grown wild-type GV oocyte (125PE, top row in [Fig 6C](#pgen.1008261.g006){ref-type="fig"}) revealed minimal if any expression of intact L1 elements with signal exisiting in the 5'UTR, which could be associated with L1's antisense promoter. Since \~46.8x10^6^ fragments (i.e. \~ 94x10^6^ reads) in 125PE libraries were mapable with perfect complementarity on the C57Bl/6 genome, these data suggest that most retrotransposition-competent L1 elements are transcriptionally silent during oocyte growth. A similar result was obtained with 75 PE data from heterozygous controls (depth \~144x10^6^ fragments, [Fig 6C](#pgen.1008261.g006){ref-type="fig"}). In contrast, coverage of intact L1 elements in *Mili* heterozygotes in RNA-seq analysis of whole testes appeared much better than in oocytes suggesting higher L1 expression during spermatogenesis ([Fig 6C](#pgen.1008261.g006){ref-type="fig"}, bottom two sets). At the same time, the loss of *Mili* yielded a mild increase L1 RNA abundance ([Fig 6C](#pgen.1008261.g006){ref-type="fig"}) but this could reflect the fact that *Mili*-mediated suppression of L1 in testes concerns only a subpopulation of cells and this increase may be diluted in the whole testes transcriptome.

Transcriptomes of double mutant oocytes showed increased abundance of reads mapping to specific L1 elements. However, coverage of such elements with perfectly mapping reads was never complete (92% in the best case, [Fig 6C](#pgen.1008261.g006){ref-type="fig"}) while the longest L1 region covered by sequencing data was 3885 nt ([Fig 6C](#pgen.1008261.g006){ref-type="fig"}). In contrast, when analyzing long L1 insertions regardless of the intact ORFs or 5' end, we could identify several elements with full or almost full coverage and even with RNA reads extending into their genomic flanks suggesting that these are *bona fide* sources of L1 transcripts ([S5 Fig](#pgen.1008261.s006){ref-type="supplementary-material"}).

Altogether, these data imply that the bulk of reads mapping to intact full-length elements are multimapping reads originating from other loci and that full-length intact L1 elements have minimal if any expression in fully-grown oocytes even in the absence of RNAi and piRNA pathways. Consistent with this notion is that suppression of RNAi and piRNA pathways in oocytes does not lead to production of detectable L1 ORF1 protein ([S6 Fig](#pgen.1008261.s007){ref-type="supplementary-material"}). This implies that, unlike derepression of L1 in *Mili*^--/--^ testes \[[@pgen.1008261.ref024]\], increased abundance of L1 transcripts in fully-grown double mutant GV oocytes is unlikely to represent significant L1 mobilization.

Discussion {#sec008}
==========

We experimentally tested whether or not RNAi acts redundantly and compensates the loss of piRNAs in the murine female germline. Existence of such a compensation was proposed previously \[[@pgen.1008261.ref031], [@pgen.1008261.ref032]\] and seemed plausible given normal fertility of female mutants of the piRNA pathway \[[@pgen.1008261.ref017]--[@pgen.1008261.ref019], [@pgen.1008261.ref030]\] and simultaneous presence of RNAi and piRNA pathways in the oocyte \[[@pgen.1008261.ref032], [@pgen.1008261.ref040]\]. Furthermore, the vertebrate female germline is not insensitive to the loss of the piRNA pathway *per se* as shown in zebrafish \[[@pgen.1008261.ref055]\]. To test the compensation hypothesis, we engineered a novel mouse mutant *Dicer*^SOM^, which could be directly crossed with a piRNA pathway mutant to obtain females deficient in both pathways in the germline in a simple crossing scheme.

*Dicer*^SOM^ mice express a tagged Dicer protein and lack expression of the short Dicer^O^ variants, which support RNAi in oocytes \[[@pgen.1008261.ref046]\]. The *Dicer*^SOM^ model is superior to our earlier *Dicer*^ΔMT^ RNAi-deficient mouse model that lacked the main *Dicer*^O^ promoter and phenocopied oocyte-specific *Dicer* knock-out phenotype \[[@pgen.1008261.ref044]\]. *Dicer*^ΔMT^ model was problematic because of varying penetrance of the phenotype due to an alternative LTR promoter that could also drive Dicer^O^ expression \[[@pgen.1008261.ref046]\]. *Dicer*^SOM^ model faithfully phenocopies the loss of Dicer in mouse oocytes including derepression of RNAi-targeted genes and retrotransposons. Low levels of the full-length Dicer remain expressed in *Dicer*^SOM/SOM^ oocytes ([Fig 2F](#pgen.1008261.g002){ref-type="fig"}). The residual full-length Dicer seems to sustain miRNA biogenesis \[[@pgen.1008261.ref044]\] but not efficient RNAi, as shown by transcriptome remodeling and phenocopy of Dicer null phenotype. This is also consistent with minimal siRNA levels produced by the full length Dicer in somatic cells from dsRNA substrates, which are capable of inducing RNAi in oocytes \[[@pgen.1008261.ref056], [@pgen.1008261.ref057]\].

For a piRNA pathway mutant, we have chosen *Mili*^DAH^ mouse model expressing catalytically dead MILI \[[@pgen.1008261.ref024]\]. MILI is involved in processing of primary piRNA transcripts \[[@pgen.1008261.ref058]\]; its prenatal or postnatal loss derails the piRNA pathway and causes male but not female sterility \[[@pgen.1008261.ref024], [@pgen.1008261.ref059]\]. When we crossed *Dicer*^SOM^ mice with *Mili*^DAH^ mice, the double mutants revealed no effect on ovarian oogenesis, up to the diplotene stage of the first meiotic division, in which oocytes remain arrested until resumption of meiosis (reviewed in \[[@pgen.1008261.ref060]\]). This shows that piRNA and RNAi pathways in the mouse female germline do not suppress an acute threat, which would manifest as an ovarian phenotype when both pathways are removed. However, long term consequences could be still sufficient for maintaining both pathways present during evolution.

Why there would be a piRNA pathway in mouse oocytes at all? As suggested during the peer review, it is possible that the piRNA pathway could be an "insurance policy" against a future retrotransposon invasion. Occasional retrotransposon invasions occurring during rodent evolution could represent sufficient selective pressure for maintaining maternal piRNA pathway. Furthermore, common germline transcription factors, such as SOHL1/2 could contribute to the presence of the piRNA pathway in male and female germlines regardless how significant would be its presence in the female germline. This notion would be supported by reduced levels of many transcripts encoding piRNA pathway components in SOHLH and SOHLH2 female mutants \[[@pgen.1008261.ref061]\] ([S7 Fig](#pgen.1008261.s008){ref-type="supplementary-material"}).

Importantly, we observed that RNAi and piRNA pathways suppress retrotransposons in oocytes in a partially redundant manner, which could be explained by the stochastic nature of evolution of substrates giving rise to siRNAs and piRNAs. The piRNA pathway is an adaptive defense, where the recognition of an invading retrotransposon is stochastic; it requires retrotransposon insertion into one of the piRNA clusters yielding piRNA production and retrotransposon repression \[[@pgen.1008261.ref062]\]. The post-transcriptionally acting RNAi also evolves stochastically in a different way. RNAi requires dsRNA, which can form when retrotransposon insertions form a transcribed inverted repeat or are transcribed antisense to produce RNAs basepairing with retrotransposon transcripts. Furthermore, some retrotransposons have intrinsic potential to produce dsRNA. In particular, L1 carries an antisense promoter in its 5'UTR and can produce sense and antisense RNAs with potential to basepair and trigger RNAi (reviewed in \[[@pgen.1008261.ref063]\]). Notably, the antisense transcription from L1 5'UTR, which exists across mammals, may represent L1's own strategy for maintaining minimal expression levels sufficient for L1 retrotransposition in *cis* \[[@pgen.1008261.ref011]\]; natural selection would otherwise yield L1s lacking the antisense promoter if it would significantly reduce L1's fitness.

It could be that L1 is not active during oocyte development because transcription factors controlling its transcription are present during different parts of the germline cycle. However, this would be inconsistent with the proposed role of L1 during fetal oocyte attrition, which requires variable L1 expression \[[@pgen.1008261.ref064]\]. Thus, it is more plausible that L1 is transcriptionally repressed in the female germline by some piRNA-independent mechanism. One of the candidate transcriptional silencing mechanisms, which can evolve and act in parallel to the piRNA pathway are Krüppel-associated box domain zinc finger proteins (KRAB-ZFPs, reviewed in \[[@pgen.1008261.ref065]\]), whose C-terminal arrays of DNA binding zinc fingers have potential to evolve into specific retrotransposon repressors. Their cofactor, TRIM28 was found enriched on some L1 subfamilies, particularly L1MdF and L1MdF2 \[[@pgen.1008261.ref066]\]. Furthermore, KRAB-ZFP *Gm6871* was proposed to selectively target L1MdF2 elements in mice \[[@pgen.1008261.ref066]\]. *Trim28* and *Gm6871* are expressed in 5dpp oocytes \[[@pgen.1008261.ref045]\] making the KRAB-ZFP system an excellent candidate for a parallel functional protection of the mouse female germline, which prevents mobilization of L1 elements in the absence of RNAi and piRNA pathways.

It should be highlighted that any interpretation of the piRNA pathway function and its loss-of-function phenotype must take into the account that the threat represented by mobile elements varies along the germline cycle and changes during evolution in species-specific manner. In any case, while there is no conclusive answer to the question why is the female germline insensitive to the loss of the piRNA pathway, our results rule out RNAi as a responsible mechanism and indicate that additional transcriptional silencing is involved in retrotransposon repression during oocyte development.

Methods {#sec009}
=======

Numerical data for graphs are provided in the [S1 File](#pgen.1008261.s014){ref-type="supplementary-material"}.

Ethics statement {#sec010}
----------------

Animal experiments were approved by the Institutional Animal Use and Care Committee (approval no. 34--2014) and were carried out in accordance with the law.

Animals {#sec011}
-------

*Mili*^DAH^ mice were kindly provided by Donal O'Carroll; this strain was characterized previously \[[@pgen.1008261.ref024]\]. *Dicer*^SOM^ mice were produced in the Transgenic Unit of the Institute of Molecular Genetics ASCR, Czech Centre for Phenogenomics.

For genotyping, tail biopsies were lysed in PCR friendly lysis buffer with 0.6 U/sample Proteinase K (Thermo Scientific) at 55 °C, with 900 rpm shaking until dissolved (approx. 2.5 h). Samples were heat-inactivated at 75 °C, 15 min. The lysate was diluted three times and 1 μl used with HighQu DNA polymerase (0.5 U/reaction) master mix for PCR. Genotyping primers are provided in [S2 Table](#pgen.1008261.s010){ref-type="supplementary-material"}. PCR program was as follows-- 95 °C, 3 min, 38 x \[95 °C, 30 s, 58 °C, 30 s, 72 °C, 1 min\], 72 °C, 3 min. PCR products were analyzed using a 1.5% agarose gel electrophoresis.

Generation of Dicer^SOM^ mice {#sec012}
-----------------------------

We first produced ESCs with the *Dicer*^SOM^ allele and then used those for producing chimeric mice and establishing *Dicer*^SOM^ line upon germline transmission of the *Dicer*^SOM^ allele. *Dicer*^SOM^ allele in ESCs \[[@pgen.1008261.ref067]\] was generated by using CRISPR-Cas9 \[[@pgen.1008261.ref068]\] mediated modification of the endogenous *Dicer* locus. Pairs of sgRNAs were designed to cleave *Dicer* genomic sequence in intron 2 (sequence of DNA targets: mDcr_i2a 5'-GTACCCAAATGGATAGAA-3', mDcr_i2b 5'-GTTGGGATGGAGGTTGTT-3') and intron 6 (sequence of DNA targets: mDcr_i6a 5'-ACTACGCTAGGTGTAAACAG-3', mDcr_i6b 5'-TGCAGTCCCCGGACGTTAAAT-3'). A template for homologous recombination was designed to contain an HA-tag at the N-terminus of *Dicer* coding sequence and DNA sequence of exon 2 to exon 7 of *Dicer* ([Fig 2A](#pgen.1008261.g002){ref-type="fig"}). Detailed description of preparation of the template for homologous recombination and its sequence are provided in the supplement ([S1 Text](#pgen.1008261.s001){ref-type="supplementary-material"}).

Upon screening \~600 ESC clones by PCR genotyping and Western blotting, we selected four ESC lines ([S1 Fig](#pgen.1008261.s002){ref-type="supplementary-material"}), which were used to produce chimeric mice. *Dicer*^SOM^ ESCs were injected into eight-cell stage of C57Bl/6 host embryos. In total, 255 chimeric embryos were constructed, which were transferred into pseudopregnant foster mothers of ICR strain background. Of 27 weaned animals, fur color indicated chimerism in seven males and one female. Five males showing the strongest chimerism were mated to C57Bl/6 females to obtain germline transmission. From \~ 140 genotyped progeny, we obtained one positive animal derived from the ESC clone 11 ([S1 Fig](#pgen.1008261.s002){ref-type="supplementary-material"}), which was subsequently crossed on the C57Bl/6 background to establish the *Dicer*^SOM^ line.

Oocyte collection {#sec013}
-----------------

Fully-grown GV oocytes were obtained from superovulated or non-stimulated 12--16 weeks old C57Bl/6 mice as described previously \[[@pgen.1008261.ref069]\]. Resumption of meiosis was prevented with 0.2 mM 3-isobutyl-1-methyl-xanthine (IBMX, Sigma). MII oocytes were obtained from animals superovulated with 7 IU of PMSG administered on day 1 and 7 IU of hCG administered 46--48 h post PMSG, mice were sacrificed 16 h post hCG. Oocytes were collected from oviducts, cumulus cells were removed by incubation with 0.1 uM hyaluronidase solution in M2 media for 3--5 min, oocytes were washed from hyaluronidase in M2 media and collected in PBS-PVP.

Cell culture and transfection {#sec014}
-----------------------------

Mouse R1 ESCs were cultured in LIF media: KO-DMEM supplemented with 15% fetal calf serum, 1x L-Glutamine (Invitrogen), 1x non-essential amino acids (Invitrogen), 50 μM β-Mercaptoethanol (Gibco), 1000 U/mL LIF (ISOKine, ORF Genetics), penicillin (100 U/mL), and streptomycin (100 μg/mL). For transfection, cells were plated on a 24-well plate, grown to 50% density and transfected using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer's protocol.

Western blotting {#sec015}
----------------

Mouse tissues were homogenized mechanically in RIPA lysis buffer (20 mM HEPES (pH 7.8), 100 mM NaCl, 1 mM EDTA (pH 8.0), 0.5% IGEPAL-25%, 1 mM fresh DTT, 0.5 mM PMSF, 1 mM NaF, 0.2 mM Na~3~VO~4~, supplemented with 2x protease inhibitor cocktail set (Millipore)), centrifuged for 15 min, at 16 000 g, 4 °C and supernatant was used for protein electrophoresis. Protein concentration was measured by Bradford assay, 40 μg of protein was loaded per late. ESCs were grown in 6-well plates. Before collection, cells were washed with PBS and lysed in RIPA lysis buffer with inhibitors.

Proteins were separated on 5.5% polyacrylamide gel and transferred on PVDF membrane (Millipore) using semi-dry blotting for 50 min, 35 V. The membrane was blocked in 5% skim milk in TTBS, Dicer was detected using rat anti-HA 3F10 monoclonal primary antibody (Sigma-Aldrich) diluted 1:2 500, membrane was incubated overnight at 4 °C in blocking solution. Washed in TTBS buffer, incubated with secondary antibody (HRP-anti-Rat diluted 1:50 000 in TTBS). Incubated for 1h at room temperature. Washed in TTBS, signal was detected using Supersignal west femto substrate (Thermo Scientific). For tubulin detection, samples were run on 10% PAA gel and incubated with anti-Tubulin (Sigma, \#T6074) mouse primary antibody diluted 1:5 000 and anti-mouse-HRP secondary antibody 1:50 000.

qPCR analyses {#sec016}
-------------

Ten oocytes per one reverse transcription (RT) reaction were collected in 1 ul PBS-PVP. 20 U of Ribolock RI (Thermofisher), 1 ug of yeast total RNA (carrier RNA) and RNase free water up to 5 ul was added and oocytes were incubated at 85 °C for 5 min for lysis. Crude lysate was used for RT with Maxima H Minus Reverse Transcriptase (Thermo Scientific). Ten oocytes from the same mouse were used for a control RT minus reaction. cDNA equivalent of a half of oocyte was used per a qPCR reaction. Maxima SYBR Green qPCR Master Mix (Thermo Scientific) was used for qPCR. qPCR was performed in technical triplicates for each biological replicate. For expression levels, we first estimated average values of the technical replicates relative to *Hprt* levels for each biological replicate and then we calculated average and standard deviation values for biological replicates.

Histology {#sec017}
---------

Ovaries were fixed in Bouin solution for 16--20 h. Next, they were washed 3x 5 min with PBS, 30 min in 50% EtOH and transferred in 70% EtOH (all steps at 4°C). Whole ovaries were dehydrated, cleared and perfused with molten paraffin during histological processing. Ovaries were then embedded in paraffin blocks and sectioned to 8 μm sections and stained with conventional hematoxylin and eosin stain. Testes were fixed in Davidson's solution for 16--20 h and processed the same way as ovaries. 6 μm tissue sections were used for Dicer detection.

Immunofluorescent staining {#sec018}
--------------------------

For analyzing microtubule defects, oocytes were isolated 16 h post hCG, fixed for 1h at room temperature in 4% PFA, permeabilized in 0.1% Triton X-100 for 10 min at room temperature (RT), washed in 2% BSA, 0.01% Tween-20 in PBS for 3x10 min, Blocked in 2% BSA, 0.01% Tween-20 in PBS for 1h, stained by primary antibody anti-β-Tubulin-Cy3 (TUB 2.1) (Abcam, ab11309) 1:200 for 1 h at room tempertaure, washed 3x 10 min in 0.01% Tween-20 in PBS, stained by 1 μg/ml DAPI for 5 min, mounted in Vectashield (Vector laboratories). Images of oocytes were acquired on DM6000 upright wide field microscope, images were processed by ImageJ. The experiment was performed twice, each time with four 17--19 weeks old *Dicer*^SOM/SOM^ females.

For detection of HA-tagged Dicer, slides with 6 μm testis sections were deparaffinized and subjected to antigen retrieval in citrate buffer (pH = 6). Sections were then permeabilized with 0.1% Triton X-100 for 15 min, blocked in 10% normal donkey serum, 0.1M glycine, 2% BSA for 1h at room tempertaure, incubated with primary antibody in blocking buffer (polyclonal rabbit anti-HA antibody (Cell signaling, 1:100) overnight at 4 °C, incubation with secondary antibody in blocking buffer for 1 h at room temperature in the dark (donkey anti-rabbit antibody conjugated with Alexa 488) diluted 1:800. Nuclei were stained with 1 μg/ml DAPI for 5 min, slides were mounted in Vectashield media (Vector labs).

RNA sequencing {#sec019}
--------------

Total RNA was extracted from 25 GV oocytes using Arcturus Picopure RNA isolation kit according to the manufacturer's protocol. RNA was eluted in 11 μl of RNAse free water. Integrity of RNA was confirmed using 2100 Bioanalyzer (Agilent Technologies). RNA-seq libraries were generated using V2 version of Ovation RNA-seq kit from Nugen. Libraries were prepared according to the manufacturer's protocol. cDNA fragmentation was performed on Bioruptor sonication device (Diagenode) as follows: 45 s ON, 30 s OFF for 21 cycles on low intensity, 100 ng of fragmented cDNA was used for library preparation. Libraries were amplified by 9 cycles of PCR and quantified by Qubit HS DNA kit, their quality was assessed using 2100 Bioanalyzer HS DNA chip. RNA-seq libraries were pooled and sequenced by 50 nt single-end reading using the Illumina HiSeq2000 platform at the Genomics Core Facility at EMBL. The RNA sequencing which included double mutants was sequenced by 75 paired-end sequencing using the Illumina NextSeq500 platform at the genomics core at IMG RNA-seq data were deposited in the Gene Expression Omnibus database under accession ID GSE132121.

Bioinformatic analyses {#sec020}
----------------------

### RNA-seq mapping and expression analysis {#sec021}

All RNA-seq data were mapped onto indexed genome using STAR 2.5.3a \[[@pgen.1008261.ref070]\]: *STAR---readFilesIn \${FILE}*.*fastq*.*gz---genomeDir \$REF_GENOME_INDEX---runThreadN 8---genomeLoad LoadAndRemove---limitBAMsortRAM 20000000000---readFilesCommand unpigz---c---outFileNamePrefix \${FILE}*.*---outSAMtype BAM SortedByCoordinate---outReadsUnmapped Fastx---outFilterMultimapNmax 99999---outFilterMismatchNoverLmax 0*.*2---sjdbScore 2*.

Read files were mapped onto mouse genome version mm10/GRCm38. Mapped reads were counted using program featureCounts \[[@pgen.1008261.ref071]\]: *featureCounts -a GENCODE*.*M15 -F \${FILE}---minOverlap 10---fracOverlap 0*.*00 -s 0 -M -O---fraction -J -T 8 \${FILE}*.*bam*.

The GENCODE gene set (GENCODE M15) was used for the annotation. The count values were normalized by *rlog* function from program suite DESeq2 \[[@pgen.1008261.ref072]\], which normalizes the data to the library size. The values of log2-fold-change were calculated among all the replicates of the corresponding conditions. The median was reported as the final value. Data were visualized as scatterplots.

### Correlation matrices {#sec022}

Correlation matrices were calculated on the same count values normalized to per kilobase per million (RPKM) units. The retrotransposons were annotated by RepeatMasker, the mapped reads were counted for the GROUP category defined in *RepeatMasker-retrotransposon-groups*.*csv* ([S3 Table](#pgen.1008261.s011){ref-type="supplementary-material"}). The values were normalized to RPKM.

Small RNA-seq data were mapped onto indexed genome using STAR 2.5.3a: *STAR---readFilesIn \${FILE}*.*fastq*.*gz---genomeDir \$REF_GENOME_INDEX---runThreadN 8---genomeLoad LoadAndRemove---limitBAMsortRAM 20000000000---readFilesCommand unpigz -c---outFileNamePrefix \${FILE}*.*---outSAMtype BAM SortedByCoordinate---outReadsUnmapped Fastx---outFilterMismatchNmax 1---outFilterMismatchNoverLmax 1---outFilterMismatchNoverReadLmax 1---outFilterMatchNmin 16---outFilterMatchNminOverLread 0---outFilterScoreMinOverLread 0---outFilterMultimapNmax 9999---alignIntronMax 1---alignSJDBoverhangMin 999999999999*

The histograms of the read lengths were calculated on the primary read alignments for the GROUP category defined in *RepeatMasker-retrotransposon-groups*.*csv* ([S3 Table](#pgen.1008261.s011){ref-type="supplementary-material"}). The potential siRNA targets ([S4 Table](#pgen.1008261.s012){ref-type="supplementary-material"}) were manually curated using the small RNA-seq datasets \[[@pgen.1008261.ref032], [@pgen.1008261.ref041], [@pgen.1008261.ref043]\] and selected annotated protein-coding genes for which (i) existed antisense endogenous 21-23nt small RNAs with \> 50 RPM average abundance and (ii) for which we could identify their origin.

### Retrotransposon expression analysis {#sec023}

For retrotransposon expression heatmap in germline ([Fig 5A](#pgen.1008261.g005){ref-type="fig"}), expression data from four different published datasets were mapped onto genome as described above GSE35005 \[[@pgen.1008261.ref048]\]; GSE70116 \[[@pgen.1008261.ref045]\], GSE45719 \[[@pgen.1008261.ref049]\], GSE41908 \[[@pgen.1008261.ref050]\], and GSE70731 \[[@pgen.1008261.ref028]\]. Next, reads overlapping one of the chosen retrotransposon subfamilies annotated by RepeatMasker \[[@pgen.1008261.ref012]\] were counted with the following restrictions: (1) only perfectly mapping reads (i. e. nM tag in SAM files = 0) were counted, (2) only reads completely overlapping retrotransposon coordinates were counted, (3) coordinates of retrotransposons overlapping with genes annotation from Ensembl database (version 93) were removed from counting, and (4) each sequencing read mapped to more than one genomic sequence belonging to the same retrotransposon subfamily was counted only once. Count values were then normalized for library size using number of perfectly mapping reads in millions to obtain RPM values. For experiments with multiple replicates the RPM was calculated as the mean RPM value over all replicates.

In order to examine expression of 2686 full-length or nearly full-length L1 elements with ORF1 and ORF2 coding sequences of expected lengths ([Fig 6C](#pgen.1008261.g006){ref-type="fig"}; [S5 Table](#pgen.1008261.s013){ref-type="supplementary-material"} in fully-grown GV oocytes (125 PE from GSE116771 \[[@pgen.1008261.ref054]\] and 75 PE from this work), RNA-seq reads were mapped onto genome using BBMap 38.63 (<http://bbmap.sourceforge.net/>) with only read pairs matching reference perfectly with no substitutions or indels allowed. All multimapping reads were retained for the analysis:

*bbmap*.*sh -Xmx60g threads = 24 in = \${FILE}\_1*.*fastq*.*gz in2 = \${FILE}\_2*.*fastq*.*gz outm = \${FILE}*.*sam outu = \${FILE}*.*unmapped*.*fq*.*gz perfectmode = t ambiguous = all pairedonly = t maxsites = 20000 nhtag = t amtag = t scoretag = t unpigz = t*.

Supporting information {#sec024}
======================

###### Supplementary methods and list of supporting information.

(DOCX)

###### 

Click here for additional data file.

###### Analysis of ESC lines for *Dicer*^*SOM*^ mouse model production by PCR and Western blotting.

The yellow marked ESC lines were used for producing chimeric mice, the clone 11 (G2) gave rise to *Dicer*^*SOM*^ animals used in the experiment.

(TIFF)

###### 

Click here for additional data file.

###### Additional micrograps documenting spindle defects in meiotically maturing DicerSOM/SOM oocytes.

Framed micrographs were used for [Fig 2A](#pgen.1008261.g002){ref-type="fig"}. Size bar = 10 μm.

(TIFF)

###### 

Click here for additional data file.

###### Comparison of transcriptomes of oocytes affected by different mutations in RNAi pathway.

\(A\) Pairwise comparisons of relative gene expression changes using DESeq2-normalized expression values. In red are depicted genes potentially targeted by RNAi (i.e. with identified antisense siRNAs). (B) Correlation matrices calculated from RPKM values all annotated genes (upper panel) and predicted siRNA targets (lower panel).

(TIFF)

###### 

Click here for additional data file.

###### Comparison of transcriptomes of oocytes affected by mutations of RNAi and/or piRNA pathway.

MA plots with the same Y-scale depict changes relative to controls (*Mili*^DAH/WT^, *Dicer*^SOM/WT^) and double mutant (*Mili*^DAH/DAH^, *Dicer*^SOM/SOM^) relative to RNAi mutant (*Mili*^DAH/WT^ *Dicer*^SOM/SOM^). Transcripts with significantly higher and lower transcript levels are shown in red and blue, respectively. Transcripts from a tandemly duplicated cluster at chromosome 12 are depicted as triangles.

(TIFF)

###### 

Click here for additional data file.

###### Selected long but not necessarily intact L1 retrotransposons from selected abundant subfamilies with the best coverage in RNA-seq data from double mutant data.

Shown are UCSC genome browser snapshots of specific L1 insertions, their % coverage and the longest covered sequence by RNA-seq data in double mutants. The samples (from the top) depict merged data from 125 nucleotide paired-end (125PE) sequencing of normal full-grown GV oocytes from Horvat et al. \[[@pgen.1008261.ref054]\], 75 nucleotide paired-end (75PE) sequencing of controls (*Mili*^DAH/WT^, *Dicer*^SOM/WT^) and double mutants (*Mili*^DAH/DAH^, *Dicer*^SOM/SOM^) from this study, and 50 nucleotide single-end (50SE) sequencing of total transcriptome of 10 days old wild-type and *Mili*^---/---^ testes\[[@pgen.1008261.ref028]\]. All RNA-seq data were scaled and are shown at the same scale 5 CPM indicated by the dashed line. The scheme below L1Md_A depicts intact ORF1 and ORF2 as lighter and darker grey rectangle, respectively.

(TIFF)

###### 

Click here for additional data file.

###### Lack of positive staining for L1 ORF1 in fully-grown oocytes.

Oocytes were stained with α-L1-ORF1 antibody (\[[@pgen.1008261.ref073]\] generous gift from Donal O' Carroll) and analyzed by confocal microscopy. Shown are 10 μm optical sections. L1 ORF1 signal is in red channel, DNA stained with DAPI is shown in blue color. Size bar = 30 μm.

(TIFF)

###### 

Click here for additional data file.

###### Expression of piRNA pathway factors in mouse newborn ovaries lacking *Sohlh1* and *Sohlh2*.

RNA-seq data were obtained from a published dataset PRJNA293873 \[[@pgen.1008261.ref061]\] and gene expression was analyzed as described in Methods.

(TIFF)

###### 

Click here for additional data file.

###### Differentially expressed genes in RNAi & piRNA mutant/RNAi mutant.

(XLSX)

###### 

Click here for additional data file.

###### Primer table.

(XLSX)

###### 

Click here for additional data file.

###### RepeatMasker retrotransposon groups.

(CSV)

###### 

Click here for additional data file.

###### siRNA target list.

(CSV)

###### 

Click here for additional data file.

###### Full length L1 table.

(CSV)

###### 

Click here for additional data file.

###### Numerical data for graphs.

(XLSX)

###### 

Click here for additional data file.
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If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Lin He

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: Taborska et al. examined redundant roles of two small RNA pathways, RNAi and piRNAs, in the silencing of retrotransposons in mouse oocytes. Specifically, this works asked if RNAi activity can explain the lack of apparent germ cell phenotypes in piRNA-deficient mouse oocytes. To address this question, the authors:

1\. generated an RNAi pathway mutant mice lacking Dicer protein (Dicer SOM). This is a tighter Dicer mutant allele compared to the one created in their previous study on the oocyte-specific Dicer isoform;

2\. characterized phenotypes of the Dicer SOM mice;

3\. generated double-mutant Dicer SOM; Mili and control animals;

4\. evaluated retrotransposon expression in single and double mutant combinations.

The main finding of this work is that lack of prominent female germ cell phenotypes in the absence of piRNAs cannot be explained by the redundancy with the RNAi pathway. A minor observation is that retrotransposon silencing by the individual small RNA pathways do not overlap completely. As such, this work clarifies the individual and combined contributions of the two small RNA pathways to retrotransposon silencing in the female germline. However, the study represents an incremental advancement in our understanding of retrotransposon regulation in the female germline. Crucially, the primary mechanism(s) that ensures retrotransposon silencing in mouse oocytes remains unknown.

Major comments:

1\. Small RNAseq data in figure one is in from Yang et al., 2016. Small RNAseq data should be acquired for single and double mutants to validate putative RNAi targets from mRNA seq, as well as show changes in global production of siRNA and piRNA with mutations.

2\. Aside from eliminating truncated Dicer variant, the Dicer SOM mouse doesn\'t seem to significantly change the overall phenotype compared to Dicer deltaMT, except from few putative RNAi targets and upregulated genes in RNA-seq. Not really significant or novel that this mouse was generated.

3\. What is a \"genomic checkpoint\" that the piRNA pathway relies on? Describe better as this is mentioned twice.

4\. Explain better the significance of including comparisons to Ago2, and differences in Dicer vs Ago2 oocyte phenotypes?

Minor comments:

Figure 2B. Missing a loading control.

Figure 2C. Needs labels, what is green and blue? What is the genotype?

Figure 2E. Endogenous control gene for qPCR?

Figure 3B. n oocytes are from how many females?

Figure 3C. Reference for initial set of genes that are sensitive to RNAi pathway?

Figure 3D. Need to validate putative RNAi targets using small RNAseq. Otherwise gene expression differences could be indirect and due to oocyte phenotypes.

Figure 3E. What is the difference between Ago2 mutants from Stein et al., 2015 in orange vs. pink? Triangle vs. square symbols?

Figure 4A. More detailed quantification of primordial follicles vs advanced follicles, maybe there is a difference at that resolution between WT and mutants.

Figure 4D. Better to use RNAseq to analyze abundance of TEs in mutants to eliminate background elements within genes that are changing as a consequence of mutation. Also, how many biological replicates per bar in qRT-PCR?

Reviewer \#2: Mammalian PIWI-piRNA pathways have been studied mostly in mouse. Mice express three PIWIs (MIWI/PIWIL1, MIWI2/PIWIL4, and MILI/PIWIL2). All three PIWI proteins are expressed at different stages during spermatogenesis, but only MILI is expressed, albeit weakly, in female germ cells. Deficiency in MIWI, MILI or MIWI2 leads to the activation of transposable elements (TEs) including L1 and IAP elements, and spermatogenesis is arrested at specific stages of spermatogenesis. Mutations in mouse PIWI genes affect the male germline but not the female germline. The authors previously identified an oocyte-specific truncated Dicer isoform, termed Dicero. This Dicer isoform produces endogenous siRNAs and together with AGO2 targets TEs and regulates their activity. These findings have led to assumptions that PIWI-piRNA pathways do not play a role during mouse oogenesis. To address the significance of redundancy of endogenous siRNA and piRNA pathways in oocytes, the authors have generated a mouse model lacking Dicero and then crossed it with MiliDAH mice expressing catalytically inactive MILI. In this study, the authors find that the simultaneous loss of endogenous siRNA and piRNA pathways does not affect oocyte development. The authors also find that endo-siRNA and piRNA pathways suppress some but not all TEs in a redundant manner. This raises the possibility that yet another TE silencing mechanism must operate in female germ cells to maintain genome integrity. Although their findings are themselves not surprising and completely expected, studies of this sort are good references and resources for further comparisons.

Minor comments:

1\. The quality of images used in Figure 2C is poor. Its legend lacks important information such as which panel shows what with which antibody.

2\. The quality of images used in Figure 3A is also poor.

3\. Figure 3C: The authors should add non-targeted genes in this experiment.

4\. Figure 4A -- C: here the authors analyze ovarian weight, histology and number of fully-grown GV oocytes using mice with age between 8 and 18 weeks. The authors should describe in legends the age in weeks of mice they use for each experiment. In my opinion, the authors should use mice with same age in weeks in these experiments. In addition, the authors' better present data with male mice in Figure 4D for the reader to understand the degree of contribution of RNAi and piRNA pathways to suppress TEs in female gonads.

Reviewer \#3: The manuscript by Taborska et al genetically explores the combined roles of the RNAi and piRNA pathways in the female mouse germ cell development through the use of advanced mouse genetics. The study is designed to address the question of whether the RNAi pathway masks a function for the piRNA pathway in the female mouse germline. An elegant new allele of Dicer is generated that forces the expression of somatic Dicer isoform throughout the entire animal inclusive of the germline. These Dicer-som are viable but present female-specific infertility. The combination of Dicer-som with the catalytically inactive MILI results in the same developmental phenotype but has a distinct molecular phenotype comparted to Dicer-som mice. This stringent genetic experiment and the molecular analysis undertaken substantiate the principal claims of the manuscript. I am intrigued by the data of Figure 5. Overall, I am supportive of publication but have concerns to be addressed:

The upregulation of RNAi targets in figure 4D & F could also be possibly presented in cumulative frequency plots (S-curves). These have traditionally been used for miRNA effects and are quantitative and very easy to understand.

The data presented in Figure 5 is not presented in the results section. This needs to be rectified.

The data presented in Figure 5 is an extremely important observation. I think it should be given some mention in the abstract. I also think the key message from the low levels of L1 transcription in the female germline and minor upregulation of L1 transcripts (compared to the male germline) in the absence of the RNAi and/or piRNA pathways would be substantiated by staining for L1 ORF1 protein. The expectation would be that it should not be detected in the respective mutant genotypes.

I think the discussion should give a sentence or two on why the piRNA-pathway expression in should be retained in the female germline of species that does abundantly express active TEs therein. The piRNA pathway is more than just the PIWI protein but requires the expression of many biogenesis factors (at least \>10). Could the expression of the pathway be an insurance policy against a future invasion?

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No
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15 Nov 2019

\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Svoboda,

Thank you very much for submitting your Research Article entitled \'Restricted and non-essential redundancy of RNAi and piRNA pathways in mouse oocytes\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

The reviewers comments are largely positive at this stage, and there are only a few comments that need to be addressed. We hope to receive a revised manuscript to incorporate these suggestions, before making an editorial decision on the paper. Your revisions should address the specific points made by reviewer 1 and 3.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 7 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Lin He

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: Overall, I am satisfied with authors\' responses.

I still have an issue with the genomic \"checkpoint\". The current draft describes piRNA clusters as \"\... specific genomic regions serving as \"checkpoints\" sensing invading mobile elements\". This is not entirely correct since a genomic region senses nothing by itself. If not expressed, its resident sequences are invisible to the piRNA system and the cell. It is an unnecessary invention that will only confuse readers, and I ask authors to refrain from using this term. For example, the same idea can be expressed as follows:

\"The piRNA pathway relies on specific genomic regions (piRNA clusters) whose expression primes piRNA production\".

Reviewer \#2: On the whole it has been improved and the authors have addressed some of the reviewers' concerns. However, it is already known that the deficiency of PIWI genes results in no discernible phenotype in female mice. In contrast, the authors previously found that the deficiency of the oocyte-specific Dicer variant causes frequent meiotic spindle defects upon resumption of meiosis. Thus, it is still not clear the rationale for why the authors try to examine possible redundancy between RNAi and piRNA pathways in mouse oocytes. The authors had better focus on characterization of Dicersom/som mutant oocytes in my opinion.

Other points:

1\. Figure 2 E & F show that expression levels of the full-length Dicer are markedly affected in Dicersom/som mutant oocytes. Why?

2\. Figure 3A: the authors should show the figures provided to response to Reviewer \#2 comments as supplementary figures.

3\. The figure showing L1 ORF1 staining in the authors response to reviewer \#3 appears to show that part of chromosomes (DAPI staining) is already excluded from the nucleus in Dicer mutants. This may imply that the deficiency of the Dicer activity already causes chromosome abnormality in early oocyte development and thus, the spindle defects observed are secondary.

4\. The figure showing expression levels of piRNA pathway genes in oocytes contains very important information in the field. Thus, the authors should show the figure in the current manuscript. Studies of this sort are good references and resources for further comparisons.

Reviewer \#3: All my concerns have been addressed.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#2: No

Reviewer \#3: No
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Dear Dr Svoboda,

We are pleased to inform you that your manuscript entitled \"Restricted and non-essential redundancy of RNAi and piRNA pathways in mouse oocytes\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Lin He

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-00984R2>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Press Queries**

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.

10.1371/journal.pgen.1008261.r006
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PGENETICS-D-19-00984R2

Restricted and non-essential redundancy of RNAi and piRNA pathways in mouse oocytes

Dear Dr Svoboda,

We are pleased to inform you that your manuscript entitled \"Restricted and non-essential redundancy of RNAi and piRNA pathways in mouse oocytes\" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Matt Lyles

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom

<plosgenetics@plos.org> \| +44 (0) 1223-442823

[plosgenetics.org](http://plosgenetics.org) \| Twitter: \@PLOSGenetics

[^1]: The authors have declared that no competing interests exist.
